The publicly traded company Sharps Technology generated approximately $17.7 million in revenue in Q3 through stake earnings and fair value gains of digital assets.

According to ChainCatcher news and GlobeNewswire reports, Sharps Technology (STSS), a publicly traded medical device sales distribution platform and SOL treasury company, announced its Q3 2025 financial report, indicating that its Solana-based financial strategy is performing well. The company raised a total of $411 million through PIPE financing, of which $267 million was in cash and stablecoins, and $144 million was in SOL tokens. As of October 31, the STSS financial pool held over 2 million SOL. In the third quarter, the company generated approximately $17.7 million in revenue from staking income and fair value gains on digital assets. As of September 30, cash and stablecoin liquidity was approximately $25.2 million. Chairman Paul K. Danner stated that adopting a Solana-based financial strategy combined with successful financing has created the strongest balance sheet in the company's history. The company has completely exited the traditional syringe manufacturing business and is focusing on two strategic priorities: medical device distribution and maximizing the value of its SOL digital asset financial portfolio.